HOME > BUSINESS
BUSINESS
- ASKA Targets 30% Overseas Sales Ratio through Southeast Asia Expansion: New President
July 9, 2025
- Fujifilm to Offer Small-Batch CDMO Services for Investigational mRNA Drugs from 2026
July 8, 2025
- Chugai, Gero Ink Joint Research on Aging-Related Diseases
July 8, 2025
- Nxera Earns US$4.8 Million Milestone as Centessa’s OX2R Drug Advances
July 7, 2025
- Keytruda Tops Japan Drug Ranking for 21st Month: Encise
July 7, 2025
- Taking on Solid Tumors - 7: Astellas Aims for Global Lead in CLDN18.2 TCEs, Building on Success with Vyloy
July 3, 2025
- Nippon Shinyaku Strikes Research Pact with Boston Children’s Hospital
July 2, 2025
- BeiGene Japan Rebrands as BeOne, Debuts PD-1 Inhibitor Tevimbra
July 2, 2025
- ASKA Moves to Counter Dalton Investments’ Rapid Share Purchase
July 2, 2025
- Mitsubishi Tanabe to Rebrand as Tanabe Pharma after Bain Takeover
July 2, 2025
- Tavalisse Now Available in South Korea for Chronic ITP: Kissei
July 2, 2025
- Ono Targets over 800 Billion Yen in FY2035 Sales under Growth Scenario: CEO
July 1, 2025
- SymBio Seeks EU Clearance to Launch Global PIII Trial of Brincidofovir
July 1, 2025
- Glaucoma Drug Gla-Alpha Approved in Singapore: Kowa
July 1, 2025
- Celltrion’s Stelara Biosimilar to Hit Shelves on July 8
July 1, 2025
- Sanofi Releases Typhim Vi, First Typhoid Vaccine in Japan
July 1, 2025
- Servier Files Tibsovo for Biliary Tract Cancer in Japan
July 1, 2025
- ASKA Rolls Out Contraceptive Pill Slinda in Japan
July 1, 2025
- 17 of 23 Japan Drug Makers Hike Average Pay in FY2024, 7 Firms Break 10-Million-Yen Mark
July 1, 2025
- J-TEC Targets 1,000 Knee OA Cases Per Year for JACC: CEO
June 30, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
